Levofloxacin 500 MG Tablets are an oral solid dosage formulation containing a defined quantity of Levofloxacin in a carefully developed tablet matrix. Consistent production requires accurate raw-material dispensing, uniform blending, controlled compression and systematic finished-product testing. For pharmaceutical companies expanding their oral pharmaceutical portfolio, this formulation can also be incorporated into a structured PCD Pharma Franchise range.
The formulation contains Levofloxacin 500 MG along with suitable pharmaceutical-grade excipients. Depending on the approved formulation, excipients may include diluents, binders, disintegrants, lubricants, glidants and other functional materials. The final composition is established through formulation development and compatibility studies to achieve consistent physical and chemical characteristics.
Development of Levofloxacin 500 MG Tablets begins with evaluating the active pharmaceutical ingredient and its compatibility with the proposed excipient system. The objective is to establish a tablet formulation with consistent weight, adequate mechanical strength, appropriate disintegration and suitable stability.
Diluents may be used to provide the required tablet bulk and improve powder-processing characteristics. Binders can support the formation of mechanically stable tablets, while disintegrants facilitate appropriate breakup after compression. Lubricants and glidants may be incorporated to improve powder flow and tablet ejection during manufacturing.
Preformulation studies can assess particle-size distribution, moisture sensitivity, flowability, compressibility and potential interactions between Levofloxacin and the selected excipients.
The quantity and combination of excipients are optimized through formulation trials. Factors such as tablet hardness, friability, disintegration and dissolution are considered while establishing the final composition.
Manufacturing starts with the controlled dispensing of Levofloxacin and all supporting excipients according to the approved batch manufacturing formula. Each raw material is checked against its applicable specification before being released for production.
Depending on the selected process, raw materials may undergo sieving, milling or other suitable preprocessing operations. These steps can help improve particle-size consistency and powder flow.
The active ingredient is incorporated into the formulation through a controlled blending process. Maintaining homogeneous distribution throughout the blend is essential for producing tablets with consistent dosage-unit characteristics.
Blending parameters such as mixing time, sequence of addition, equipment load and operating conditions are established during process development. Representative samples may be evaluated for blend uniformity before compression.
Depending on the formulation technology, the blend may be processed using direct compression or an appropriate granulation method. If granulation is used, parameters such as granule size, moisture content and flow properties can be monitored before compression.
The prepared blend is compressed using suitable tooling and controlled machine settings. Compression force, machine speed and powder-feeding conditions influence tablet weight, thickness, hardness and overall integrity.
During compression, in-process checks can be performed at predetermined intervals. Average weight and weight variation are monitored to maintain consistency across the production batch.
Tablet hardness is evaluated to ensure adequate strength for handling, packaging and transportation. At the same time, compression parameters are optimized to maintain suitable disintegration characteristics.
Friability testing provides an assessment of resistance to mechanical abrasion. Visual inspection can identify defects such as capping, lamination, chipping, sticking or uneven tablet surfaces.
Disintegration testing can also be included in the quality-control program. Dissolution performance may be evaluated according to the applicable product specification and validated testing procedure.
Controlled compression parameters help establish a reproducible manufacturing process and consistent finished-tablet characteristics.
Finished-product testing confirms that Levofloxacin 500 MG Tablets meet their established specifications. Identification and assay of Levofloxacin can be performed using suitable validated analytical methods.
Depending on the approved specification, testing may include uniformity of dosage units, average weight, weight variation, hardness, thickness, friability, disintegration and dissolution.
Related substances and degradation-related parameters may also be evaluated where applicable. These analytical controls help monitor the chemical quality of the formulation throughout manufacturing and storage.
Stability studies are conducted under defined storage conditions to evaluate changes in the product over time. Samples may be tested at predetermined intervals for appearance, assay, degradation profile, dissolution, disintegration and other relevant quality attributes.
Stability evaluation helps establish suitable storage requirements and provides supporting information for determining the appropriate packaging system and product shelf life.
Packaging selection is an important part of the development process for Levofloxacin 500 MG Tablets. The selected packaging system should provide suitable protection against moisture, contamination and physical damage during storage and transportation.
Blister packs, strip packs or other approved pharmaceutical packaging formats may be selected according to the product's stability characteristics and market requirements. Packaging materials should be evaluated for compatibility with the formulation, while seal integrity can be monitored to maintain product protection.
The final packaging artwork should include the approved composition, batch information, manufacturing details, storage conditions and other applicable regulatory particulars. Consistent packaging specifications also help maintain a professional and standardized product presentation.
For pharmaceutical manufacturers and marketers, Levofloxacin 500 MG Tablets can complement a broader oral solid-dose portfolio. Accurate dispensing, controlled blending, optimized compression, analytical testing and stability monitoring contribute to consistent product development.
For companies developing a diversified PCD Pharma Franchise portfolio, standardized product specifications, documented manufacturing procedures and suitable packaging can support organized product management and consistent presentation across the pharmaceutical distribution network.
Levofloxacin 500 MG Tablets with formulation, manufacturing, quality control, stability, packaging and PCD Pharma Franchise product development details.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech